You are here: Home » Companies » News
Business Standard

Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons

Aurobindo Pharma | Sun Pharma | Jubilant

Press Trust of India  |  New Delhi 


Leading drug firms Aurobindo Pharma, and are recalling different products in the for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA).

While is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based is recalling a drug used to increase the production of natural tears in eyes.

Similarly, Cadista is recalling a drug which is used to treat different inflammatory conditions.

Cadista Pharmaceuticals is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences.

The stated that USA Inc, a unit of Hyderabad-based drug major, is recalling 4,33,809 vials of Cyanocobalamin injection for being a "Subpotent Drug".

The New Jersey-based firm initiated the recall on April 5.

The US health regulator noted that US-based Sun Pharmaceutical Industries Inc is recalling 73,030 boxes of Cequa (cyclosporine ophthalmic solution) for being a "Subpotent Drug".

Besides, there was low out-of-specification results obtained for assay and the presence of particulate matter in the affected lot, stated as reasons for the company to initiate the recall.

The company, a subsidiary of Sun Pharma, initiated the recall on April 1, this year.

The noted that Salisbury-based Jubilant Cadista Pharmaceuticals Inc is recalling 19,222 bottles of Methylprednisolone tablets for being "Subpotent".

As per the US health regulator, New Jersey-based Macleods Pharma USA Inc is also recalling 4,872 bottles of a drug used to treat or prevent osteoporosis, manufactured at Baddi (Himachal Pradesh) due to "Failed content uniformity specifications."

The USFDA has classified the recalls as Class III, which is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."

The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, April 24 2022. 12:04 IST